These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9007106)

  • 1. Study design problems of DATATOP study analysis.
    Mäki-Ikola O; Heinonen E
    Ann Neurol; 1996 Dec; 40(6):946-8. PubMed ID: 9007106
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
    LeWitt PA
    J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
    BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract]   [Full Text] [Related]  

  • 5. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiparkinson efficacy of deprenyl. DATATOP Steering Committee of Parkinson Study Group.
    Oakes D
    Ann Neurol; 1993 Oct; 34(4):634. PubMed ID: 8215256
    [No Abstract]   [Full Text] [Related]  

  • 9. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
    Breteler MM
    BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
    Tariska I; Gallai M
    Orv Hetil; 1983 Sep; 124(38):2309-14. PubMed ID: 6415577
    [No Abstract]   [Full Text] [Related]  

  • 11. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
    Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Rudolph A; Lang AE;
    Neurology; 2005 Jan; 64(1):87-93. PubMed ID: 15642909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline and mortality in Parkinson's disease.
    Olanow CW; Fahn S; Langston JW; Godbold J
    Ann Neurol; 1996 Dec; 40(6):841-5. PubMed ID: 9007088
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom.
    Head J; Ben-Shlomo Y; Lees AJ
    Clin Neuropharmacol; 1998; 21(4):265-6. PubMed ID: 9704171
    [No Abstract]   [Full Text] [Related]  

  • 15. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 17. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroprotective and neurorestorative therapy in Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out.
    Landau WM
    Neurology; 1990 Sep; 40(9):1337-9. PubMed ID: 2118239
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical inquiries. What is the best initial treatment of Parkinson's disease?
    Schreck J; Kelsberg G; Rich J; Ward R
    J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.